Michael Todinca, M.D., Neuromuscular Neurologist, Joins Baptist Health Miami Neuroscience Institute

• by

• July 13, 2026

Effect of nusinersen on respiratory function in patients with spinal muscular atrophy: an 18-month single-center prospective study

• by Tianjian Luo, Lingling Xu, Wen Tang, Liuyi Huang, Yijuan Li, Zhihui Yue

• July 8, 2026

Disease-specific divergence of inflammatory and metabolic biomarkers in neurocritical neuromuscular disorders

• by Sezgin Kehaya, Erdi Şensöz

• May 13, 2026

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

• by Kathryn Wighton

• March 30, 2026

• 2 min